Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Endotronix, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Endotronix, Inc.

Regulatory records
21
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 21 FDA records to the applicant name Endotronix, Inc.. It includes 1 original PMA approval. 4 entries are PMA supplements. 16 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jun 20, 2024 to Oct 29, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MOM appears in 21 of the 21 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P230040, with 21 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 6 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 1415 W. Diehl Rd., Suite 500w, Naperville, IL, 60563. Recorded on P230040/S030, decision dated Oct 29, 2026.

Changes described in PMA records

P230040/S030: Cordella Pulmonary Artery Sensor System

The FDA record for P230040/S030 lists a normal 180-day track supplement with no user fee, dated October 29, 2026, for Endotronix, Inc.'s Cordella Pulmonary Artery Sensor System under product code MOM. The stated change is the addition of an alternate ethylene oxide (EO) gas sterilization facility, categorized as a location change affecting manufacturer, sterilizer, packager or supplier. Because the identifier links this to original PMA P230040, it is a supplement rather than a new approval of the whole system.

The record does not identify the new facility, its location, the sterilization cycle parameters, or any validation data. The stated purpose describes a manufacturing and sterilization-site addition only; it is not evidence of clinical safety or effectiveness of the device itself, and no such conclusion should be drawn from this notice.

FDA approval-order wording

addition of alternate Ethyle Oxide (EO) gas sterilization facility

Oct 29, 2026 · Normal 180 Day Track No User Fee

P230040/S035: Cordella Pulmonary Artery Sensor System (CorPASS)

The FDA recorded decision OK30 on 2026-10-20 for P230040/S035, a 30-Day Notice supplement to the Cordella Pulmonary Artery Sensor System (CorPASS) held by Endotronix, Inc. The supplement falls under the process change category for manufacturer, sterilizer, packager or supplier. The stated scope is removal of a redundant inspection process of the Coil PCB subassemblies. The device is listed in the implantable hemodynamic system category under the Cardiovascular specialty with product code MOM.

This action covers a manufacturing process change for a named subassembly rather than a new approval of the whole CorPASS system. The source record does not describe the inspection method removed, the rationale for treating it as redundant, or any verification data supporting the change; those details would sit in the supplement submission, which is not included here. No clinical, efficacy or patient-selection conclusions follow from this record, and the source gives no information on current labeling or post-change performance.

FDA approval-order wording

removal of a redundant inspection process of the Coil PCB subassemblies

Oct 20, 2026 · 30-Day Notice

P230040/S031: Cordelia Pulmonary Artery Pressure Sensor System (CorPASS)

The FDA recorded an approval decision on 2026-10-16 for supplement P230040/S031, submitted by Endotronix, Inc. for the Cordelia™ Pulmonary Artery Pressure Sensor System (CorPASS). The supplement is classified as a Real-Time Process submission with the reason Labeling Change - Indications/instructions/shelf life/tradename. The device falls under the implantable hemodynamic system category, cardiovascular specialty, product code MOM.

The recorded scope is limited to revisions to the Instructions for Use concerning recommendations for guidewire selections. This action amends labeling within the existing P230040 application rather than constituting a new approval of the whole system. The source record does not include the revised IFU text, the specific guidewire recommendations, or the original approval date, so the content of the change and any clinical implications remain unknown from this data alone.

FDA approval-order wording

revisions to the Instructions for Use (IFU) for the Cordelia Pulmonary Artery regarding recommendations for guidewire selections

Oct 16, 2026 · Real-Time Process

P230040/S034: Cordella Pulmonary Artery Sensor System (CorPASS)

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-14, for P230040/S034, a supplement to the Cordella Pulmonary Artery Sensor System (CorPASS) held by Endotronix, Inc. The supplement falls under the process change category covering manufacturer, sterilizer, packager or supplier, and the recorded statement describes automating an incoming functional inspection test method. The device is listed in the implantable hemodynamic system category within cardiovascular devices, product code MOM.

The notice addresses a manufacturing test-method change rather than a new approval of the CorPASS system as a whole; the underlying original approval and its clinical labeling are not restated here. The source record includes no documents, so the specific test method, affected manufacturing site and any inspection performance data remain unknown. Whether the automation alters inspection sensitivity or acceptance criteria cannot be determined from the available fields.

Readers should treat OK30 as the recorded decision on this supplement only. No clinical, efficacy or patient-selection conclusions follow from a process change of this kind, and none are asserted here.

FDA approval-order wording

automating an incoming functional inspection test method

Oct 14, 2026 · 30-Day Notice

P230040/S033: Cordella Pulmonary Artery Sensor System (CorPASS)

The FDA record for P230040/S033 lists a 30-Day Notice for the Cordella Pulmonary Artery Sensor System (CorPASS) under product code MOM, decided OK30 on 2026-09-25. The stated reason is a process change affecting manufacturer, sterilizer, packager or supplier. The listed change is that acceptance criteria for the Interrogation Inspection method were updated. The record does not specify which acceptance criteria changed, their prior or new values, or what the inspection covers.

The S033 identifier places this as a supplement to PMA P230040 rather than a new approval of the whole system. The stated purpose is a manufacturing process change; the record does not present it as evidence of safety or clinical effectiveness, and it adds no indication, trial or performance detail. Because the statement is brief, the scope of the revision stays unknown beyond the field label.

FDA approval-order wording

updated acceptance criteria to the Interrogation Inspection method

Sep 25, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Endotronix, Inc.PMA supplementOct 29, 2026FDA
Endotronix, Inc.PMA supplementOct 20, 2026FDA
Endotronix, Inc.PMA supplementOct 16, 2026FDA
Endotronix, Inc.PMA supplementOct 14, 2026FDA
Endotronix, Inc.PMA supplementSep 25, 2026FDA
Endotronix, Inc.PMA supplementAug 13, 2026FDA
Endotronix, Inc.PMA supplementMar 2, 2026FDA
Endotronix, Inc.PMA supplementFeb 24, 2026FDA
Endotronix, Inc.PMA supplementFeb 17, 2026FDA
Endotronix, Inc.PMA supplementFeb 13, 2026FDA
Endotronix, Inc.PMA supplementJan 9, 2026FDA
CorPASS SystemP230040/S015
Endotronix, Inc.PMA supplementDec 19, 2025FDA
CorPASS SystemP230040/S024
Endotronix, Inc.PMA supplementNov 25, 2025FDA
Endotronix, Inc.PMA supplementOct 22, 2025FDA
CorPASS SystemP230040/S022
Endotronix, Inc.PMA supplementOct 6, 2025FDA
Endotronix, Inc.PMA supplementSep 30, 2025FDA
Endotronix, Inc.PMA supplementSep 29, 2025FDA
Endotronix, Inc.PMA supplementSep 10, 2025FDA
CorPASS SystemP230040/S018
Endotronix, Inc.PMA supplementAug 26, 2025FDA
Endotronix, Inc.PMA supplementAug 14, 2025FDA
Endotronix, Inc.PMA approvalJun 20, 2024FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.